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Donna K. Arnetti, Treva Ricea and Dabeeru C. RaoaBackground Metabolic syndrome and its risk factors are
predictors of cardiovascular events. Metabolic syndrome is
also directly associated with echocardiographic
phenotypes.
Methods The current study is the first to investigate the
factors associated with both metabolic syndrome risk
factors and echocardiographic phenotypes and assess their
heritability. Multivariate factor analysis was performed on 15
traits in 1393 African–Americans and 1133 whites, as well
as stratified by type 2 diabetes mellitus status.
Results Factor analysis with varimax rotation established
four to five latent factors across ethnicities and diabetes
mellitus stratifications. Among metabolic syndrome risk
factors, blood pressure was the most highly correlated with
cardiactraits.Thefactordomains, intheorderoftheproportion
of variance explained, were ‘left ventricle wall thickness’, ‘left
ventricle geometry’, ‘blood pressure’, ‘BMI–insulin’, and
‘lipid–insulin’. Factor analysis without any rotation identified
special (cross domain) metabolic syndrome–
echocardiographic factors, ‘blood pressure–left ventricle
geometry’ and ‘blood pressure–left ventricle dimension-wall
thickness’ inwhites. Fifty to57%of the total original risk factor
variance was explained by the latent factors. Heritability was
highest for BMI–insulin (37–53%), lowest for ‘blood
pressure’ factors (15–27%), and intermediate for metabolic
syndrome–echocardiographic factors.
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Metabolic syndrome (MetS), which comprises clustering
of obesity, insulin resistance, glucose intolerance, dys-
lipidemia, and elevated blood pressure (BP), is gaining
epidemic proportion in Western countries [1–8]. The
prevalence of MetS is between 20–30%, with higher
values in African–Americans, Hispanic–Americans, and
women [6,9,10]. Studies have shown that compared with
healthy individuals, the odds of developing cardiovascular
disease (CVD) is higher, ranging from 1.26 to 3.86, in
patients with MetS, depending on the study population
and the applied MetS definitions [10–15].
MetS not only predicts CVD but also associates with
abnormal structural and dimensional cardiovascular traits.For example, it was shown that ventricular wall thickness
was higher in patients with MetS than in their healthy
counterparts [16–19]. Left ventricular dimension and
mass, which can be clinically assessed by echocardiogra-
phy, a noninvasive ultrasound technique, are higher in
patients with MetS [20]. MetS has also been reported to be
associated with diastolic dysfunction [16,21,22] and greater
arterial stiffness [23]. These findings suggest a direct
relationship among MetS risk fa ctors and cardiac pheno-
types. However, to the best of our knowledge, few data are
available on the multivariate relationship among MetS risk
factors and echocardiographic (ECHO) cardiac measure-
ments. Although previous studies have found positive
associations between MetS and cardiovascular traits, the
strength of specific correlations among individual MetSrized reproduction of this article is prohibited.
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Hence, this study was undertaken to investigate the
relationship among ECHO phenotypes and MetS risk
factors. Utilizing factor analysis, we aimed to identify
MetS–ECHO domains in the Hypertension Genetic Epi-
demiology Network (HyperGEN) and examine their
heritability.
Methods
Study population
HyperGEN is one of four networks of the National
Heart, Lung, and Blood Institute (NHLBI) Family Blood
Pressure Program (FBPP), which studies genetic aspects
of high BP and related conditions. Two ethnic groups,
whites and African–Americans, were recruited in the
HyperGEN study [24]. They represented hypertensive
sibships with at least two members diagnosed with
hypertension before the age of 60, a random sample of
age-matched subjects from the same source population
that included normotensive controls, unmedicated adult
offspring of hypertensive siblings, and parents of hyper-
tensive sibling pairs. Questionnaires, blood samples,
clinical data, and ECHO measurements were collected
from participants at four HyperGEN centers (Minnea-
polis, Minnesota; Salt Lake City, Utah; Forsyth County,
North Carolina; and Birmingham, Alabama). Exclusion
criteria included hypertension secondary to kidney
disease or other primary causes and type I diabetes.
Of the total 3550 HyperGEN participants who underwent
echocardiography, 1547 were whites, 1996 African–
Americans, and seven of other ethnicities. We focused
on siblings and their offspring. Within these samples,
participants with a fasting time of less than 8 h or any
missing values in a full set of 15 traits studied were
excluded from the analysis. As a result, we analyzed the
phenotypes of 1133 whites and 1393 African–Americans.
A participant was classified with type 2 diabetes mellitus
based on the participant’s self report, use of antidiabetic
medication or insulin treatment at the time of the clinical
visit, or the presence of fasting plasma glucose level of
126 mg/dl or more, with age of 40 years or more at the
onset of diabetes mellitus [25,26].
Echocardiography
Echocardiograms were performed by a standard protocol as
described previously [27] using two-dimensional (2D)
guided M-mode and Doppler measurements. Correct
orientation of imaging planes and Doppler recordings were
carried out according to the standard protocol. A compu-
terized review station equipped with digitizing tablet and
monitor screen overlay was used to calibrate and perform
measurements. The measurements were first taken by
sonographers or physicians centrally trained at the Reading
Center in New York and verified by highly experienced
investigators who were blinded to the clinical data [28,29].opyright © Lippincott Williams & Wilkins. UnauthPhenotypic data preparation
The 15 risk variables under investigation were fasting
glucose (GLUC), fasting insulin (INS), fasting triglycer-
ides, high-density lipoprotein cholesterol (HDLC), body
massindex(BMI),medication-adjustedsystolicbloodpres-
sure (SBP), medication-adjusted diastolic blood pressure
(DBP), heart rate (HR), left ventricular internal diastolic
dimension (LVID), diastolic posterior wall thickness
(PWT), diastolic relative wall thickness (RWT), LV mass
indexed to height2.7 (LVMI), aortic root diameter (ARD),
arterial stiffness defined by pulse pressure over stroke
volume (PP/SV), and LV midwall shortening (MWS).
The peak velocities of mitral valve early filling phase and
atrial filling phase were not included in our study because
the sample size would have been significantly reduced.
The SBP and DBP of the participants with prescribed
antihypertensive medication were adjusted for antihy-
pertensive medication(s) effect by the method described
by Wu et al. [30] and applied in the HyperGEN study to
obtain the pretreatment BP levels for various classes
of medications.
All variables underwent appropriate distribution trans-
formations when deemed necessary to achieve standard
normal distributions with mean values of zero and variance
of one. The Transreg procedure in SAS (version 9.1.3 for
Linux; SAS Institute, Cary, North Carolina, USA) was used
to find the best power transformation. Log transformation
was applied to INS, HDLC, triglycerides, BMI, RWT,
LVMI, PWT, and PP/SV. The inverse of squared trans-
formation for GLUC (1/GLUC2) and cubic power trans-
formation for MWS (MWS3) were applied in both whites
and African–Americans. The remaining variables did not
require transformation before covariate adjustments.
All 15 variables were adjusted within race and sex by
regressing on age, age2, age3, and field centers, and only
significant terms were retained. Stepwise regression using
the REG procedure of SAS was used for covariate adjust-
ments. Age and field-center effects were removed from
both the means and the variances, and standardized
residuals were derived. Outliers beyond 4 SD and more
than 1 SD away from the next internal data point were
eliminated from the final distribution. Skewness and kur-
tosis values of less than two were checked and required as
two important normal distribution indicators. Final stan-
dardized residuals (phenotypes), with a mean of zero and a
variance of one, were utilized in the factor analysis.
Statistical analysis
Factoranalysiswasperformedusingthefactanalfunctionof
the S-PLUS version 7 software (Linux OS) with the option
of the maximum likelihood estimate (MLE) method.
Factor analysis was performed separately in whites and
African–Americans. Within each ethnic group, the effects
of diabetes mellitus were investigated by running factor
analyses either including or excluding participants withorized reproduction of this article is prohibited.
C1362 Journal of Hypertension 2008, Vol 26 No 7diabetes mellitus. Furthermore, the effect of varimax
rotation in factor analysis was also explored by running
the analysis with and without rotation. When varimax
rotation is applied, the variance of the squared loadings
across a factor is maximized, in turn, maximizing the inde-
pendence of the factors [26,31].
To determine the factor analysis model with the most
appropriate number of factors, we concurrently applied
the following criteria. At least two risk variables in a latent
factor were required with loadings of about 0.4 or more.
Because the variables were prestandardized and normally
distributed, the loadings of the analysis were essentially
the correlation coefficients between each original variable
and the latent factor. The sum of squared loadings per
latent factor had to be more than or approximately one. In
addition, the MLE model was required to be significant
(P< 0.05). The MLE significance employed in the
analysis tested whether the number of latent factors
selected was sufficient to explain the model. These
stringent criteria of the analysis ensured that significant
contributions of the original variables to the latent factors
were present in each factor analysis model.
Results
Among the studied participants in the subsample with no
missing values in any of the 15 variables, there were 99
whites and 241 African–Americans with diabetes melli-
tus. The whites had higher triglyceride levels. In contrast,
African–Americans tended to have higher BMI, GLUC,opyright © Lippincott Williams & Wilkins. Unautho
Table 1 Phenotypic characteristics of participants in this study
(including and excluding patients with type 2 diabetes)
Variables
White African–American
All DMa All DM
Number of
participants
1133 1034 1393 1152
Women
participants (%)
50.13 49.52 65.47 63.98
Age (years) 4914b 4914 4613 4413
BMI (kg/m2) 29.35.7 29.05.6 32.27.5 31.87.5
GLUC (mg/dl) 101.433.5 96.726.4 108.446.8 95.016.3
INS (mU/ml) 8.17.1 7.75.5 10.79.2 10.08.3
SBP (mmHg) 134.326.4 133.126.3 145.528.4 142.026.6
DBP (mmHg) 77.812.8 77.612.9 84.515.0 83.715.1
HDLC (mg/dl) 46.613.5 46.913.5 53.315.1 53.515.1
Triglycerides
(mg/dl)
166.8118.0 160.6108.9 108.281.6 100.559.3
HR (beats/min) 68.211.0 67.810.9 70.812.0 69.811.6
LVMI2.7 (g/m2 7) 80.020.0 79.319.1 85.822.5 84.421.9
LVID (cm) 5.20.5 5.20.5 5.20.5 5.20.5
PWT (cm) 0.80.1 0.80.1 0.90.1 0.90.1
RWT 0.30.1 0.30.1 0.30.1 0.30.1
ARD (cm) 3.40.4 3.40.4 3.30.4 3.30.4
PP/SV 0.70.2 0.70.2 0.70.2 0.70.2
MWS (%) 18.02.3 18.12.2 17.32.4 17.52.4
ARD, aortic root diameter; DBP, medication-adjusted diastolic blood pressure;
GLUC, glucose; HDLC, high-density lipoprotein cholesterol; HR, heart rate; INS,
insulin; LVID, left ventricle internal diastolic dimension; LVMI, left ventricle mass
index; MWS, left ventricle midwall shortening; PP/SV, arterial stiffness as pulse
pressure over stroke volume; PWT, diastolic posterior wall thickness; RWT,
diastolic relative wall thickness; SBP, medication adjusted systolic blood
pressure. aDM, excluding type 2 diabetes mellitus subjects. b MeanSD.INS, BP, HDLC, HR, and LVMI (Table 1). Among
whites and African–Americans, age, GLUC, and trigly-
cerides were only slightly lower in individuals without
diabetes.
Pearson’s correlation among adjusted variables showed
similar patterns regardless of ethnicity or the presence/
absence of type 2 diabetes (Table 2). In general, MetS
and ECHO variables correlated more strongly among
themselves than between the two groups. However,
several significant correlations between MetS and ECHO
variables in both ethnicities were observed with P values
of less than 0.0001: BMI with LVID (whites: all, 0.27;
excluding diabetes mellitus, 0.28; African–Americans:
all, 0.35; excluding diabetes mellitus, 0.36), PWT
(whites: 0.25; 0.25; African–Americans: 0.29; 0.30), and
ARD (whites: 0.15; 0.16; African–Americans: 0.18; 0.19).
INS was correlated with PWT (0.20; 0.20) and RWT
(0.14; 0.14) in whites, and in African–Americans, INS
(0.12; 0.15) and GLUC (–0.12; –0.10) were correlated
with PWT. SBP was significantly correlated with four
ECHO variables in whites (LVMI, 0.18; 0.20; LVID,
0.13; 0.15; PWT, 0.21; 0.21; PP/SV, 0.30; 0.31) and in
African-Americans SBP (LVMI, 0.32; 0.32; LVID, 0.18;
0.18; PWT, 0.33; 0.33; RWT, 0.17; 0.18; PP/SV, 0.35; 0.31;
MWS, –0.18; –0.19) and DBP (LVMI, 0.29; 0.25; PWT,
0.19; 0.20; RWT, 0.12; 0.13; ARD, 0.13; 0.13; PP/SV, 0.21;
0.18; MWS, –0.15; –0.17) were correlated with six
ECHO variables. High correlations were observed
between BMI–INS, SBP–DBP, and among BMI,
GLUC, INS, HDLC, and triglycerides. Glucose was
negatively correlated because of the inverse transform-
ation performed (see Methods). Among the ECHO vari-
ables, high correlations were observed between LVMI–
LVID, LVMI–PWT, LVID–RWT, and PWT–RWT.
HR was weakly correlated with INS in all models but
with a correlation coefficient of not more than 0.2. These
observed phenotypic correlations served as the founda-
tion of the factor structures derived in the factor analysis.
Factor analysis with varimax rotation, and with or without
diabetes mellitus, in general showed similar factor pat-
terns across ethnicities. (Table 3). Of the 15 original MetS
and ECHO variables, five latent factors were identified
that were labeled ‘LV wall thickness’, ‘LV geometry,’
‘BMI–INS’, ‘lipid–INS’, and ‘BP’. The ‘LV wall thick-
ness’ factor was composed of PWT, RWT, LVMI, and
negative MWS contributions, and explained about 15%
of the original variance. The ‘LV geometry’ factor,
represented by LVMI, LVID, and negative contributions
of RWT, had the second highest proportion (about 12%)
of the variance explained. The ‘BMI–INS’ factor, includ-
ing high loadings of BMI and INS, explained about 8% of
the overall variance including 12% in African–Americans
without diabetes. The ‘BP’ factor explained about 11% of
the original variance across all groups. The ‘lipid–INS’
factor, which primarily included triglycerides, HDLC,rized reproduction of this article is prohibited.
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Table 2 Correlation matrix of the variables included in factor analysis
BMI GLUC INS SBP DBP HDLC Triglycerides HR LVMI LVID PWT RWT ARD PP/SV MWS
Whites, lower triangle,
all data (n¼1133)
Whites, upper triangle, all data excluding diabetes mellitus (n¼1034)
BMI 0.25§ 0.57§ 0.23§ 0.09y 0.24§ 0.23§ 0.08M 0.06 0.28§ 0.25§ 0.07M 0.16§ 0.03 0.11y
GLUC 0.26§ 0.31§ 0.15§ 0.09y 0.18§ 0.19§ 0.19§ 0.003 0.05 0.05 0.03 0.03 0.03 0.01
INS 0.55§ 0.31§ 0.21§ 0.12§ 0.36§ 0.37§ 0.20§ 0.02 0.08y 0.20§ 0.14§ 0.09y 0.11y 0.10y
SBP 0.24§ 0.16§ 0.21§ 0.69§ 0.04 0.14§ 0.07M 0.20§ 0.15§ 0.21§ 0.09y 0.06M 0.31§ 0.10y
DBP 0.07M 0.07M 0.10y 0.68§ 0.04 0.08y 0.11y 0.11y 0.05M 0.11y 0.08M 0.12§ 0.06 0.03
HDLC 0.24§ 0.22§ 0.36§ 0.01 0.03 0.48§ 0.02 0.03 0.08M 0.09y 0.05 0.10y 0.01 0.04
Triglycerides 0.22§ 0.26§ 0.37§ 0.15§ 0.08M 0.50§ 0.10y 0.006 0.01 0.08M 0.08M 0.05 0.11y 0.06M
HR 0.08M 0.22§ 0.21§ 0.07M 0.11y 0.03 0.10y 0.10y 0.17§ 0.05 0.15§ 0.01 0.16§ 0.13§
LVMI 0.05 0.01 0.01 0.18§ 0.10y 0.03 0.01 0.10y 0.61§ 0.65§ 0.19§ 0.17§ 0.02 0.34§
LVID 0.27§ 0.04 0.08y 0.13§ 0.04 0.07M 0.01 0.18§ 0.61§ 0.09y 0.51§ 0.27§ 0.18§ 0.10y
PWT 0.25§ 0.08y 0.20§ 0.21§ 0.10y 0.10y 0.08y 0.05 0.64§ 0.09y 0.78§ 0.15§ 0.08y 0.39§
RWT 0.07M 0.05 0.14§ 0.10y 0.07M 0.05 0.08M 0.16§ 0.17§ 0.52§ 0.78§ 0.03 0.17§ 0.28§
ARD 0.15§ 0.02 0.09y 0.05 0.11y 0.10y 0.05 0.01 0.16§ 0.26§ 0.14§ 0.03 0.16§ 0.01
PP/SV 0.03 0.05 0.10y 0.30§ 0.05 0.01 0.12§ 0.17§ 0.01 0.18§ 0.10y 0.20§ 0.16§ 0.18§
MWS 0.11y 0.04 0.09y 0.10y 0.04 0.04 0.06M 0.14§ 0.34§ 0.11y 0.38§ 0.27§ 0.01 0.18§
African–Americans,
lower triangle, all
data (n¼1393)
African–Americans, upper triangle, all data excluding (n¼1152)
BMI 0.32§ 0.54§ 0.18§ 0.03 0.26§ 0.17§ 0.05 0.04 0.36§ 0.30§ 0.03 0.19§ 0.14§ 0.10y
GLUC 0.29§ 0.44§ 0.09y 0.01 0.25§ 0.27§ 0.11y 0.01 0.08y 0.10y 0.04 0.09y 0.04 0.05
INS 0.51§ 0.37§ 0.06M 0.06M 0.39§ 0.35§ 0.17§ 0.08y 0.09y 0.15§ 0.08y 0.10y 0.08y 0.05
SBP 0.17§ 0.13§ 0.03 0.75§ 0.02 0.09y 0.09y 0.32§ 0.18§ 0.33§ 0.18§ 0.07M 0.31§ 0.19§
DBP 0.04 0.02 0.07y 0.75§ 0.08y 0.04 0.13§ 0.25§ 0.09y 0.20§ 0.13§ 0.13§ 0.18§ 0.17§
HDLC 0.24§ 0.24§ 0.35§ 0.03 0.08y 0.38§ 0.02 0.04 0.02 0.08y 0.05 0.04 0.01 0.06M
Triglycerides 0.17§ 0.29§ 0.33§ 0.07y 0.03 0.42§ 0.13§ 0.05 0.01 0.03 0.02 0.05 0.01 0.01
HR 0.06M 0.19§ 0.18§ 0.09y 0.13§ 0.06M 0.16§ 0.12§ 0.14§ 0.03 0.09y 0.06 0.17§ 0.13§
LVMI 0.04 0.02 0.07y 0.32§ 0.23§ 0.02 0.02 0.11§ 0.63§ 0.70§ 0.22§ 0.25§ 0.01 0.48§
LVID 0.35§ 0.09y 0.10y 0.18§ 0.07y 0.03 0.05 0.12§ 0.64§ 0.21§ 0.46§ 0.34§ 0.19§ 0.19§
PWT 0.29§ 0.12§ 0.12§ 0.33§ 0.19§ 0.07y 0.03 0.02 0.70§ 0.21§ 0.75§ 0.20§ 0.03 0.50§
RWT 0.03 0.05 0.05 0.17§ 0.12§ 0.04 0.002 0.08y 0.20§ 0.47§ 0.75§ 0.04 0.15§ 0.32§
ARD 0.18§ 0.07y 0.08y 0.07y 0.13§ 0.004 0.05 0.06M 0.23§ 0.32§ 0.19§ 0.04 0.17§ 0.11y
PP/SV 0.12§ 0.03 0.07y 0.35§ 0.21§ 0.03 0.01 0.16§ 0.01 0.17§ 0.05M 0.16§ 0.18§ 0.15§
MWS 0.09y 0.07y 0.06M 0.18§ 0.15§ 0.07y 0.03 0.13§ 0.47§ 0.21§ 0.49§ 0.30§ 0.11y 0.17§
ARD, aortic root diameter; DBP, medication-adjusted diastolic blood pressure; GLUC, glucose; HDLC, high-density lipoprotein cholesterol; HR, heart rate; INS, insulin;
LVID, left ventricle internal diastolic dimension; LVMI, left ventricle mass index; MWS, left ventricle midwall shortening; PP/SV, arterial stiffness as pulse pressure over stroke
volume; PWT, diastolic posterior wall thickness; RWT, diastolic relative wall thickness; SBP, medication adjusted systolic blood pressure. MP<0.05. yP<0.01.
§P<0.0001.and INS, explained about 9% of the original variables
variance.
In analyses without rotation of factors, ‘LV wall thick-
ness’ explained about 14–15% of the original variance of
the 15 variables (Table 4), and the latent factors ‘BP’ and
‘LV geometry’ were combined in whites into a new
MetS–ECHO factor. This ‘BP–LV geometry’ factor,
which captured high loadings of SBP and LVID and
moderate loadings of DBP and LVMI, explained 13%opyright © Lippincott Williams & Wilkins. Unauth
Table 3 Loadings, sums of squared loadings, and proportion variabilit
Factor domains Samples BMI GLUC INS SBP DBP HDLC Triglyce
LV wall thickness White
African–American 0.12
LV geometry White 0.14
African–American 0.23 0.18
BP White 0.10 0.98 0.68
African–American 0.96 0.76
Lipid–INS White 0.25 0.35 0.49 0.67 0.73
African–American 0.31 0.47 0.57 0.58 0.64
BMI–INS White 0.87 0.19 0.48 0.15
African–American 0.81 0.16 0.38 0.17
ARD, aortic root diameter; DBP, medication-adjusted diastolic blood pressure; GLUC,
LVID, left ventricle internal diastolic dimension; LVMI, left ventricle mass index; MWS, left
volume; PWT, diastolic posterior wall thickness; RWT, diastolic relative wall thickness; S
b P. Var., proportion of the original variables variance explained from a factor.of the original variance. A third factor was ‘BP–LV
dimension-wall thickness’, which had a high loading of
SBP and LVID, moderate loadings of DBP and RWT,
and a lower contribution of PP/SV, together explained
11% of the original variance. In both ethnicities, the
fourth factor ‘BMI–INS’ was composed of obesity
(BMI) and INS (GLUC, INS) domains but with a slight
difference. Whites had an additional contribution from
the lipids domain (HDLC and triglycerides), whereas
in African–Americans, LVMI had a negative loadingorized reproduction of this article is prohibited.
y explained by factor domains (all subjects, varimax rotation)
rides HR LVMI LVID PWT RWT ARD PP/SV MWS SS L.a P. Var.b
0.64 0.97 0.82 0.10 0.38 2.21 0.15
0.51 0.15 0.92 0.91 0.43 2.17 0.14
0.20 0.63 0.99 0.55 0.24 0.20 0.10 1.85 0.12
0.12 0.76 0.98 0.33 0.36 0.32 0.14 0.29 2.08 0.14
0.32 1.58 0.11
0.17 0.13 0.12 0.40 1.76 0.12
0.16 1.45 0.10
0.28 0.10 1.50 0.10
0.12 0.13 0.15 0.12 1.13 0.08
0.17 0.16 0.18 0.14 0.12 0.99 0.07
glucose; HDLC, high-density lipoprotein cholesterol; HR, heart rate; INS, insulin;
ventricle midwall shortening; PP/SV, arterial stiffness as pulse pressure over stroke
BP, medication adjusted systolic blood pressure. a SS L., sum of squared loadings.
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Table 4 Loadings, sums of squared loadings, and proportion variability explained by factor domains (all subjects, no rotation)
Factor
Domains Samples BMI GLUC INS SBP DBP HDLC Triglycerides HR LVMI LVID PWT RWT ARD PP/SV MWS SSL.a P. Var.a
LV wall
thickness
White 0.20 0.17 0.10 0.59 0.96 0.82 0.12 0.38 2.19 0.15
African–
American
0.20 0.10 0.54 0.93 0.82 0.13 0.43 2.09 0.14
BP–LV
geometry
White 0.33 0.14 0.19 0.75 0.47 0.11 0.53 0.75 0.20 0.28 0.20 0.14 2.01 0.13
LV geometry African–
American
0.35 0.10 0.18 0.12 0.64 1.00 0.21 0.47 0.32 0.17 0.21 2.05 0.14
BP–LV
dimension
wall
thickness
White 0.66 0.49 0.11 0.19 0.33 0.66 0.47 0.16 0.37 1.67 0.11
BP African–
American
0.11 0.12 0.98 0.75 0.12 0.22 0.31 0.28 0.39 0.15 1.97 0.13
BMI–INS White 0.63 0.38 0.70 0.46 0.45 0.22 0.26 1.59 0.11
African–
American
0.77 0.35 0.61 0.16 0.33 0.28 0.16 0.38 0.12 0.11 1.49 0.10
ARD, aortic root diameter; DBP, medication-adjusted diastolic blood pressure; GLUC, glucose; HDLC, high-density lipoprotein cholesterol; HR, heart rate; INS, insulin;
LVID, left ventricle internal diastolic dimension; LVMI, left ventricle mass index; MWS, left ventricle midwall shortening; PP/SV, arterial stiffness as pulse pressure over stroke
volume; PWT, diastolic posterior wall thickness; RWT, diastolic relative wall thickness; SBP, medication adjusted systolic blood pressure. a SS L., sum of squared loadings;
P. Var., proportion variance of the original variables explained by factor domains.(borderline at 0.4). These factors explained, respectively,
11 and 10% of the original variance. Similar factors were
found in participants without diabetes mellitus (results
not shown).
Finally, Table 5 summarizes the proportion of the
original variance explained by each factor and each
factor’s additive genetic heritability. The heritability
coefficients were highest for factor ‘BMI–INS’ (37–
53%) and lowest for ‘BP’ (15–27%). ECHO factors
‘LV wall thickness’ and ‘LV geometry’ had moderate
(30–40%) heritability, with a trend for lower heritability
for ‘LV wall thickness’ in African–Americans. The com-
bined MetS–ECHO factors present in whites showed
heritability in the range of 18–38%. Latent factors
explained 50–57% of the 15 original risk factors variance.
Discussion
Our study investigated the associations among MetS and
cardiac phenotypes simultaneously for the first time inopyright © Lippincott Williams & Wilkins. Unautho
Table 5 Proportion of the original variance explained by factor domain
Domain Factor
Varimax rotation
Whites African–Am
All Diabetes mellitus All Dia
Prop. Var.; h2 Prop. Var.; h2 Prop. Var.; h2 Pr
ECHO LV wall thickness 15; 406a 15; 407 14; 53 1
LV geometry 12; 346 12; 336 14; 376 1
MetS BMI–INS 8; 477 8; 377 7; 467 1
Lipid–INS 10; 406 8; 477 10; 357
BP 11; 153 11; 266 12; 245 1
MetS–ECHO BP–LV geometry
BP–LV dimension
wall thickness
Total proportion
of Variance
56 54 57
BP, blood pressure; ECHO, echocardiography; INS, insulin; LV, left ventricle; MetS, m
domains and the heritabilities are expressed in percentage.the HyperGEN study through an exploratory factor
analysis. We identified several latent patterns that reduce
the complexity of a large number of phenotypes. Of the
latent factors found, three of them (‘BMI–INS’, ‘BP’ and
‘lipid–INS’) were similar to those reported previously in
different study populations [26,32–35].
Factor analysis with varimax rotation explained 54–56%
of the original variance in whites and 51–57% in African–
Americans (Table 5). Similarly, in the analysis without
rotation, variance explained was only slightly reduced to
50% and 51–52% of the original variances in whites and
African–Americans, respectively.
Kraja et al. [26] utilized the full samples of the Hyper-
GEN study and showed that the prevalence of MetS as
defined by the ATP-III criteria was 34% in African–
Americans and 39% in whites. Also, they found that MetS
topology had a predominance of obesity, hypertension,
and dyslipidemia. The higher prevalence of MetS in thisrized reproduction of this article is prohibited.
s and their heritability estimates
No rotation
ericans Whites African–Americans
betes mellitus All Diabetes mellitus All Diabetes mellitus
op. Var.; h2 Prop. Var.; h2 Prop. Var.; h2 Prop. Var.; h2 Prop. Var.; h2
5; 185 15; 397 15; 397 14; 0 14; 144
3; 347 14; 386 14; 347
2; 479 11; 376 11; 356 10; 538 11; 459
1; 195 13; 275 13; 235
13; 184 14; 195
11; 295 11; 387
52 50 50 51 52
etabolic syndrome. a Proportion of the original variance explainedSD, by factor
CFactors of metabolic syndrome and ECHO in HyperGEN study Huang et al. 1365study population than in the general US population can
be explained by the ascertainment of the original Hyper-
GEN network for hypertension [9]. Regardless of ethni-
city, in our study samples, participants with MetS were
older and had higher BMI, GLUC, INS, SBP, DBP, and
triglycerides levels and lower HDLC levels. MetS
participants also had a larger LVMI, LV dimension,
thicker walls, and stiffer vessels, in agreement with
previous findings [16,17,20].
The current study identified two cardiac factor domains,
‘LV wall thickness’ and ‘LV geometry’, which had the
highest proportion of variances explained. These findings
suggest that of all 15 risk factors, those contributing to
LV wall thickness and LV geometry, were important in
the latent factors created.
Of special interest in the current study was the discovery
of MetS–ECHO factor domains, ‘BP–LV geometry’, and
‘BP–LV dimension-wall thickness’ in whites. These
factors were not found under the varimax rotation factor
analysis because applying such an orthogonal rotation
made the derived factors more independent. The vari-
ables that loaded most strongly into these two factors
were SBP and LVID, followed by either DBP and LVMI
or DBP and RWT, respectively for ‘BP–LV geometry’ or
‘BP–LV dimension-wall thickness’. LVMI, LVID, and
RWT are useful measurements in assessing LV hyper-
trophy (LVH), a manifestation of preclinical cardiovas-
cular disease with 18–78% prevalence in hypertensive
patients [36–38]. It is known that the prevalence of MetS
and LVH is higher in African–Americans. Our study
found intertwined relations between MetS and ECHO
phenotypes in the African–American sample. The fact
that BP was correlated significantly with cardiac traits in
our study is consistent with results in the Strong Heart
Study. Chinali et al. [39] reported BP to be the only MetS
risk factor that was associated with LV geometric altera-
tions. Our finding on the association between BP and
LVMI agrees with the results from Gardin et al. [40] and
Fox et al. [41].
Inclusion or exclusion of subjects with diabetes mellitus
had no important effect on the factor structures. A neg-
ligible effect of diabetes mellitus on MetS factor patterns
was also reported in previous studies on the same study
network and on Pima Indians [26,32].
Our findings of four to five factor models offer further
insight for understanding the relationship among MetS
and ECHO variables. In addition, the heritability coeffi-
cients of the factors showed that several of the identified
latent variables might be good candidates for genetic
linkage and association analyses due to the moderate
to high heritability. Although these results are interest-
ing, our study has a limitation in the recruitment of
the original study population. The HyperGEN networkopyright © Lippincott Williams & Wilkins. Unauthwas originally ascertained for hypertensive probands and
their families. Such a background for these participants
may limit the generality of this study’s results to the
entire adult population. In addition, although we
addressed the confounding effect of medications on
BP measurements (by medication adjustment of SBP
and DBP), the same was not performed for patients with
diabetes and dyslipidemia. If participants were treated
for diabetes and/or given lipid-lowering medications,
then their GLUC, INS, HDL, or triglyceride measure-
ments were confounded by medication. It should also be
noted that BP-independent effects of drugs on ECHO
parameters and side effects on glucose and lipids might
exist.
The results of the current study provide empirical insight
into the relationship among MetS and cardiovascular
traits. In addition to its specific results, our study also
presents a methodological paper showing a way to derive
factor scores in a multifactorial analysis. Future studies
will need to determine whether these factor analysis
structures replicate in different (e.g. healthy) popu-
lations. Further, as the derived factors capture intercor-
relation among variables, they provide greater power
that can be utilized in linkage and association analyses
to discover the potential genetic foundation of these traits.
Acknowledgements
Primary Centers and Investigators of HyperGEN.
University of Utah (Network Coordinating Center, Field
Center, and Molecular Genetics Lab): Steven C. Hunt,
PhD (Network Director and Field Center PI); Mark F.
Leppert, PhD (Molecular Genetics PI); Jean-Marc
Lalouel, MD, DSc; Robert B. Weiss, PhD; Roger R.
Williams, MD (late); Janet Hood. University of Alabama
at Birmingham (Field Center): Cora E. Lewis, MD,
MSPH (PI); Albert Oberman, MD, MPH.; Donna Arnett,
PhD; Phillip Johnson; Christie Oden. Boston University
(Field Center): Richard H. Myers, PhD (PI); R. Curtis
Ellison, MD; Yuqing Zhang, MD; Jemma B. Wilk, DSc;
Luc Djouss, MD, DSc; Jason M. Laramie; Greta Lee
Splansky, MS. University of Minnesota (Field Center
and Biochemistry Lab): James S. Pankow, PhD (Field
Center PI); Michael B. Miller, PhD; Michael Li, PhD;
John H. Eckfeldt, MD, PhD; Anthony A. Killeen, MD,
PhD; Catherine Leiendecker-Foster, MS; Jean Bucksa;
GregRynders.UniversityofNorthCarolina(FieldCenter):
Kari E. North, PhD (PI); Barry I. Freedman, MD; Gerardo
Heiss, MD. Washington University (Data Coordinating
Center): D.C. Rao, PhD (PI.); Charles Gu, PhD; Treva
Rice,PhD;AldiT.Kraja,DSc,PhD;GangShi,PhD;YunJu
Sung, PhD; Karen L. Schwander, MS; Stephen Mandel;
Shamika Ketkar; Matthew Brown; Michael A. Province,
PhD; Ingrid Borecki, PhD; Derek Morgan.
Weil Cornell Medical College (Echo Reading Center):
R.B. Devereux, MD; Giovanni de Simone, MD, Jonathanorized reproduction of this article is prohibited.
C1366 Journal of Hypertension 2008, Vol 26 No 7N. Bella, MD. National Heart, Lung, & Blood Institute:
Cashell Jaquish, PhD; Dina Paltoo, PhD. This hyperten-
sion network is funded by cooperative agreements (U10)
with NHLBI: HL54471, HL54472, HL54473, HL54495,
HL54496, HL54497, HL54509, HL54515.
There are no conflicts of interest.
References
1 Bouguerra R, Ben Salem L, Alberti H, Ben Rayana C, El Atti J,
Blouza S, et al. Prevalence of metabolic abnormalities in the
Tunisian adults: a population based study. Diabetes Metab 2006; 32:
215–221.
2 Daskalopoulou SS, Athyros VG, Kolovou GD, Anagnostopoulou KK,
Mikhailidis DC. Definitions of metabolic syndrome: where are we now?
Curr Vasc Pharmacol 2006; 4:185–197.
3 Kozan O, Oquz A, Abaci A, Erol C, Ongen Z, Tamizhan A, Celik S.
Prevalence of the metabolic syndrome among Turkish adults. Eur J Clin
Nutr 2007; 61:548–553.
4 Liu J, Hanley AJ, Young TK, Harris SB, Zinman B. Characteristics and
prevalence of the metabolic syndrome among three ethnic groups in
Canada. Int J Obes 2006; 30:669–676.
5 McEvoy JP, Meyere JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L,
et al. Prevalence of the metabolic syndrome in patients with
schizophrenia: baseline results from the Clinical Antipsychotic
Trials of Intervention Effectiveness (CATIE) schizophrenia trial and
comparison with national estimates from NHANES III. Schizophr Res
2005; 80:19–32.
6 Meigs JB. Epidemiology of the metabolic syndrome. Am J Manag Care
2002; 8:S283–292.
7 Reaven P. Metabolic syndrome. J Insur Med 2004; 36:132–142.
8 Weng X, Liu Y, Ma J, Wang W, Yang G, Caballero B. An urban–rural
comparison of the prevalence of the metabolic syndrome in Eastern China.
Public Health Nutr 2007; 10:131–136.
9 Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome
among US adults: findings from the Third National Health and Nutrition
Examination Survey. JAMA 2002; 287:356–359.
10 Meigs JB, Wilson PW, Nathan DM, D’Agostino RB Sr, William K,
Haffner SM. Prevalence and characteristics of the metabolic syndrome in
the San Antonio Heart and Framingham Offspring Studies. Diabetes 2003;
52:2160–2167.
11 Vague P, Raccah D. The syndrome of insulin resistance. Horm Res 1992;
38:28–32.
12 Deepa M, Froog S, Datta M, Deepa R, Mohan V. Prevalence of metabolic
syndrome using WHO, ATPIII and IDF definitions in Asian Indians: the
Chennai Urban Rural Epidemiology Study (CURES-34). Diabetes Metab
Res Rev 2007; 23:127–134.
13 Gami AS, Witt BJ, Howard DE, Erwin PJ, Gami LA, Somers VK, Montori VM.
Metabolic syndrome and risk of incident cardiovascular events and death: a
systematic review and meta-analysis of longitudinal studies. J Am Coll
Cardio 2007; 4:403–414.
14 Katzmarzyk PT, Janssen I, Ross R, Church TS, Blair SN. The importance of
waist circumference in the definition of metabolic syndrome:
prospective analyses of mortality in men. Diabetes Care 2006; 29:
404–409.
15 Kurl S, Laukkanen JA, Niskanen L, Laaksonen D, Sivenius J, Nyyssonen K,
Salonen JT. Metabolic syndrome and the risk of stroke in middle-aged men.
Stroke 2006; 37:806–811.
16 Lind L, Andersson P, Andrent B, Hanni A, Lithel HO. Left ventricular
hypertrophy in hypertension is associated with the insulin resistance
metabolic syndrome. J Hypertens 1995; 13:433–438.
17 Cuspidi C, Meani S, Fusi V, Severgnini B, Valerio C, Catini E, et al.
Metabolic syndrome and target organ damage in untreated essential
hypertensives. J Hypertens 2004; 22:1991–1998.
18 Burchfiel CM, Skelton TN, Andrew ME, Garrison RJ, Arnett DK,
Jones DW, Taylor HA Jr. Metabolic syndrome and echocardio-
graphic left ventricular mass in blacks: the Atherosclerosis
Risk in Communities (ARIC) Study. Circulation 2005; 112:819–827.
19 Ferrara LA, Cardoni O, Mancini M, Zanchetti A. Metabolic syndrome and
left ventricular hypertrophy in a general population. Results from the Gubbio
Study. J Hum Hypertens 2007; 21:795–801.
20 Grandi AM, Maresca AM, Giudici E, Laurita E, Marchesi C, Solbiati F, et al.
Metabolic syndrome and morphofunctional characteristics of the left
ventricle in clinically hypertensive nondiabetic subjects. Am J Hypertens
2006; 19:199–205.opyright © Lippincott Williams & Wilkins. Unautho21 De las Fuentes L, Brown AL, Mathews SJ, Waggoner AD, Soto PF, Gropler
RJ, Davila-Roman VG. Metabolic syndrome is associated with abnormal left
ventricular diastolic function independent of left ventricular mass. Eur Heart
J 2007; 28:553–559.
22 Masugata H, Senda S, Goda F, Yoshihara Y, Yoshikawa K, Fujita N, et al.
Left ventricular diastolic dysfunction as assessed by echocardiography in
metabolic syndrome. Hypertens Res 2006; 29:897–903.
23 Ferreira I, Henry BMA, Twisk JWR, van Mechelen W, Kemper HCG,
Stehouwer CDA. The metabolic syndrome, cardiopulmonary fitness, and
subcutaneous trunk fat as independent determinants of arterial stiffness.
Arch Intern Med 2005; 165:875–882.
24 Williams RR, Rao DC, Ellison RC, Arnett DK, Heiss G, Oberman A, et al.
NHLBI Family Blood Pressure Program: methodology and recruitment in
the HyperGEN network. Ann Epidemiol 2000; 10:389–400.
25 Hunt KJ, Heiss G, Sholinsky PD, Province MA. Familial history of the
metabolic disorders and the metabolic syndrome: the NHLBI Family Heart
Study. Genetic Epidemiol 2000; 19:395–409.
26 Kraja AT, Hunt SC, Pankow JS, Myers RH, Heiss G, Lewis CE, et al.
An evaluation of the metabolic syndrome in the HyperGEN study.
Nutr Metab 2005; 2:17–25.
27 Devereux RB, Roman MJ. Evaluation of cardiac function and vascular struc-
ture and function by echocardiography and other noninvasive techniques. In:
Laragh JH, Brenner BM, editors. Hypertension: pathophysiology, diagnosis
and management, 2nd ed. New York, USA: Raven Press Ltd; 1995.
28 Devereux RB, de Simone G, Palmieri V, Oberman A, Hopkins P, Kitzman
DW, et al. Relation of insulin to left ventricular geometry and function in
African American and Caucasian hypertensive adults: the HyperGEN
study. Am J Hypertens 2002; 15:1029–1035.
29 Tang W, Arnett DK, Devereux RB, Atwood LD, Kitzman DW, Rao DC.
Linkage of left ventricular early diastolic peak filling velocity to chromosome
5 in hypertensive African Americans: the HyperGEN echocardiography
study. Am J Hypertens 2002; 15:621–627.
30 Wu J, Kraja AT, Oberman A, Lewis CE, Ellison RC, Arnett DK, et al. A
summary of the effects of antihypertensive medications on measured blood
pressure. Am J Hypertens 2005; 18:935–942.
31 Gorsuch RL. Factor analysis. Hillsdale, NJ, USA: Lawrence Erlbaum
Associates, Inc.; 1983.
32 Hanson RL, Imperatore G, Bennet PH, Knowler WC. Components of the
‘‘metabolic syndrome’’ and incidence of type 2 diabetes. Diabetes 2002;
51:3120–3127.
33 Meigs JB, D’Agostino RB, Wilson PW, Cupples LA, Nathan DM, Singer
DE. Risk variable clustering in the insulin resistance syndrome. The
Framingham Offspring Study. Diabetes 1997; 46:1594–1600.
34 Shen BJ, Todaro JF, Niaura R, McCaffery JM, Zhang J, Spiro A, Ward KD.
Are metabolic risk factors one unified syndrome? Modeling the structure of
the metabolic syndrome X. Am J Epidemiol 2003; 157:701–711.
35 Wang JJ, Lappalainen J, Qiao Q, Hu G, Miettinen ME, Tuomlehto J. The
metabolic syndrome defined by factor analysis and incident type 2 diabetes
in a Chinese population with high postpranidial glucose. Diabetes Care
2004; 27:2429–2437.
36 Adebiyi AA, Ogah OS, Aje A, Ojji DB, Adebayo AK, Oladapo OO, Falase
AO. Echocardiographic partition values and prevalence of left ventricular
hypertrophy in hypertensive Nigerians. BMC Med Imaging 2006; 6:10.
37 Cuspidi C, Lonati L, Macca G, Sampieri L, Fusi V, Michev I, et al. Prevalence
of left ventricular hypertrophy and carotid thickening in a large selected
hypertensive population: impact of different echocardiographic and
ultrasonographic diagnostic criteria. Blood Press 2001; 10:142–149.
38 Wachtell K, Bella JN, Liebson PR, Gerdts E, Dahlof B, Aalto T, et al. Impact
of different partition values on prevalences of left ventricular hypertrophy
and concentric geometry in a large hypertensive population: the LIFE study.
Hypertension 2000; 35:6–12.
39 Chinali C, Devereux RB, Howard BV, Roman MJ, Bella JN, Liu JE, et al.
Comparison of cardiac structure and function in American Indians with and
without the metabolic syndrome (the Strong Heart study).Am JCard 2004;
93:40–44.
40 Gardin JM, Wagenknecht LE, Anton-Culver H, Flack J, Gidding S, Kurosaki
T, et al. Relationship of cardiovascular risk factors to echocardiographic left
ventricular mass in healthy young black and Caucasian adult men and
women. The CARDIA study. Coronary Artery Risk Development in Young
Adults. Circulation 1995; 1:380–387.
41 Fox E, Taylor H, Andrew M, Han H, Mohamed E, Garrison R, Skelton T.
Body mass index and blood pressure influences on left ventricular mass
and geometry in African Americans: the Atherosclerotic Risk In
Communities (ARIC) study. Hypertension 2004; 44:55–60.rized reproduction of this article is prohibited.
